Key Details
Price
$5.63PE Ratio
70.38Annual ROE
4.85%Beta
0.92Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 3, 2017Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.
India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases.
FAQ
- What is the ticker symbol for MannKind?
- Does MannKind pay dividends?
- What sector is MannKind in?
- What industry is MannKind in?
- What country is MannKind based in?
- When did MannKind go public?
- Is MannKind in the S&P 500?
- Is MannKind in the NASDAQ 100?
- Is MannKind in the Dow Jones?
- When was MannKind's last earnings report?
- When does MannKind report earnings?
- Should I buy MannKind stock now?